Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
Standard
Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs). / Hambach, Julia; Riecken, Kristoffer; Cichutek, Sophia; Schütze, Kerstin; Albrecht, Birte; Petry, Katharina; Röckendorf, Jana Larissa; Baum, Natalie; Kröger, Nicolaus; Hansen, Timon; Schuch, Gunter; Haag, Friedrich; Adam, Gerhard; Fehse, Boris; Bannas, Peter; Koch-Nolte, Friedrich.
In: CELLS-BASEL, Vol. 9, No. 2, 29.01.2020.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
AU - Hambach, Julia
AU - Riecken, Kristoffer
AU - Cichutek, Sophia
AU - Schütze, Kerstin
AU - Albrecht, Birte
AU - Petry, Katharina
AU - Röckendorf, Jana Larissa
AU - Baum, Natalie
AU - Kröger, Nicolaus
AU - Hansen, Timon
AU - Schuch, Gunter
AU - Haag, Friedrich
AU - Adam, Gerhard
AU - Fehse, Boris
AU - Bannas, Peter
AU - Koch-Nolte, Friedrich
N1 - Hinweis des Journals "Author(s) to whom correspondence should be adressed" ist unspezifisch (mal Erst+Letzt, mal "mehrere" Letzt...), daher als Indiz für geteilte Autorenschaft nicht geeignet!
PY - 2020/1/29
Y1 - 2020/1/29
N2 - The NAD-hydrolyzing ecto-enzyme CD38 is overexpressed by multiple myeloma and other hematological malignancies. We recently generated CD38-specific nanobodies, single immunoglobulin variable domains derived from heavy-chain antibodies naturally occurring in llamas. Nanobodies exhibit high solubility and stability, allowing easy reformatting into recombinant fusion proteins. Here we explore the utility of CD38-specific nanobodies as ligands for nanobody-based chimeric antigen receptors (Nb-CARs). We cloned retroviral expression vectors for CD38-specific Nb-CARs. The human natural killer cell line NK-92 was transduced to stably express these Nb-CARs. As target cells we used CD38-expressing as well as CRISPR/Cas9-generated CD38-deficient tumor cell lines (CA-46, LP-1, and Daudi) transduced with firefly luciferase. With these effector and target cells we established luminescence and flow-cytometry CAR-dependent cellular cytotoxicity assays (CARDCCs). Finally, the cytotoxic efficacy of Nb-CAR NK-92 cells was tested on primary patient-derived CD38-expressing multiple myeloma cells. NK-92 cells expressing CD38-specific Nb-CARs specifically lysed CD38-expressing but not CD38-deficient tumor cell lines. Moreover, the Nb-CAR-NK cells effectively depleted CD38-expressing multiple myeloma cells in primary human bone marrow samples. Our results demonstrate efficacy of Nb-CARs in vitro. The potential clinical efficacy of Nb-CARs in vivo remains to be evaluated.
AB - The NAD-hydrolyzing ecto-enzyme CD38 is overexpressed by multiple myeloma and other hematological malignancies. We recently generated CD38-specific nanobodies, single immunoglobulin variable domains derived from heavy-chain antibodies naturally occurring in llamas. Nanobodies exhibit high solubility and stability, allowing easy reformatting into recombinant fusion proteins. Here we explore the utility of CD38-specific nanobodies as ligands for nanobody-based chimeric antigen receptors (Nb-CARs). We cloned retroviral expression vectors for CD38-specific Nb-CARs. The human natural killer cell line NK-92 was transduced to stably express these Nb-CARs. As target cells we used CD38-expressing as well as CRISPR/Cas9-generated CD38-deficient tumor cell lines (CA-46, LP-1, and Daudi) transduced with firefly luciferase. With these effector and target cells we established luminescence and flow-cytometry CAR-dependent cellular cytotoxicity assays (CARDCCs). Finally, the cytotoxic efficacy of Nb-CAR NK-92 cells was tested on primary patient-derived CD38-expressing multiple myeloma cells. NK-92 cells expressing CD38-specific Nb-CARs specifically lysed CD38-expressing but not CD38-deficient tumor cell lines. Moreover, the Nb-CAR-NK cells effectively depleted CD38-expressing multiple myeloma cells in primary human bone marrow samples. Our results demonstrate efficacy of Nb-CARs in vitro. The potential clinical efficacy of Nb-CARs in vivo remains to be evaluated.
U2 - 10.3390/cells9020321
DO - 10.3390/cells9020321
M3 - SCORING: Journal article
C2 - 32013131
VL - 9
JO - CELLS-BASEL
JF - CELLS-BASEL
SN - 2073-4409
IS - 2
ER -